I suspect a DNA vaccine will have lower cost of manufacture than...

I suspect a DNA vaccine will have lower cost of manufacture than the known competitors -- quality control should also be less an issue. However, Admedus does need to at least match clinical outcomes of competitors.

Depending on any adjuncts required & delivery method, I would hope any products coming out of Admedus are stable at room temperature - not sure about the competitors. Also interesting is whether this vaccine will be a candidate for nano-patch delivery rather than traditional injection. That tech was developed in Qld too -- but now owned by a US company commercialising it.

Phase 2 commencing this year is good news.